BioDelivery Sciences (BDSI) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results
March 16, 2015 4:04 PM EDTRALEIGH, N.C., March 16, 2015 /PRNewswire/ --Â BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today reported financial results for the fourth quarter and fiscal year ended December 31, 2014, and reviewed its significant 2014 accomplishments and anticipated milestones for 2015.
Corporate Update and Recent Accomplishments
BUNAVAIL (buprenorphine and naloxone) buccal film: Approved and launched in the U.S. for the maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support. BUNAVAIL is BDSI's second FDA approved product and the first that it is... More